Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

NCT01203020 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma

Interventions

DRUG: Busulfan
DRUG: Fludarabine

Sponsor

West Virginia University